SGLT2 inhibitors confer greater risk reductions for major adverse cardiovascular events in older adults with type 2 diabetes ...

Opens in a new tab or window SGLT2 inhibitors were more cardioprotective in older people, but reduced HbA1c less with age. GLP-1 receptor agonists were more cardioprotective in younger people ...

The report tipped demand for GLP-1 drugs, SGLT2 inhibitors and Kerendia to help add $20 billion to the value of the market in 10 years.

Since GLP-1-based therapy is a promising novel treatment of type 2 diabetes, the strategy to inhibit the enzyme has been explored. Several DPP-4 inhibitors are in clinical development; these are ...

Of over 350,000 adults with type 2 diabetes, thyroid cancer risk was significantly higher within the first year after GLP-1 agonist initiation compared with SGLT2 inhibitors, DPP-4 inhibitors ...

The researchers found that both SGLT2 inhibitors and GLP-1 agonists were associated with a lower risk of major cardiovascular events, but the drug effects varied with the patients’ age.

GLP-1RA and SGLT2 inhibitor combination therapy was associated with better cardiorenal outcomes than monotherapy among patients with type 2 diabetes. The cardiorenal benefits of sodium-glucose ...

The first study examines TNF-a levels in patients receiving the GLP-1 agonist Wegovy ® or Ozempic ® who show signs of increased inflammation associated with sarcopenia, which is the progressive loss ...

as well as other contextual barriers which are important (for example, financial barriers ... documented reason for not taking a GLP-1 agonist or SGLT-2 inhibitor were excluded, as were those ...